Skip to main content

Table 2 T/C% values and BWL% of the different treatments in the MNHOC124, MNHOC218 and MNHOC239 PDXs

From: Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts

 

MNHOC124

MNHOC218

MNHOC239

 

T/C% (day)

BWL% (day)

T/C% (day)

BWL% (day)

T/C% (day)

BWL% (day)

PTX/BEV

5.4 (38)

-

6.6 (46)

0.8 (31)

23.8 (64)

-

PTX/MEK

55.5 (38)

-

45.2 (46)

5.6 (38)

49.2 (61)

0.3 (28)

BEV/MEK

27.5 (38)

2.3 (31)

16.2 (16)

0.2 (38)

25.5 (61)

-

PTX/BEV/MEK

5.5 (38)

1.3 (31)

0.7 (46)

4.7 (31)

13.7 (47)

-

  1. T/C% values are considered significant of drug response when ≤42% (NCI guidelines). BWL: Body Weight Loss